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Hydroxyurea does not appreciably reduce JAK2
V617F allele burden in patients with poly-
cythemia vera or essential thrombocythemia
Variable results about the effects of hydroxyurea on
the burden of mutant allele in patients with myeloprolif-
erative neoplasms (MPN) harboring the JAK2V617F muta-
tion have been produced recently. In a retrospective sin-
gle center study in 48 JAK2V617F-positive patients with
polycythemia vera (PV) or essential thrombocythemia
(ET), the granulocyte V617F allele burden was found to
remain stable over a median follow-up time of 34 and 23
months in polycythemia vera and essential thrombo-
cythemia patients, respectively, independently of
whether patients were already or not under hydroxyurea
treatment at the time of first sampling. On the other
hand, in 5 of 6 patients in whom hydroxyurea was start-
ed during the follow up, a statistically significant
decrease of JAK2V617F allele burden was observed at six
months compared to baseline level; furthermore, the lev-
els of mutant allele were found to increase again after
stopping the treatment.1 However, while in 9 essential
thrombocythemia patients analyzed by Hussein et al.
hydroxyurea treatment did not modify the V617F allele
burden,2 Girodon et al. reported a significant reduction of
mutant allele in 36 patients with polycythemia vera or
essential thrombocythemia from a median of 43% at
diagnosis to 24% at a median follow up of 15 months
after starting hydroxyurea.3 Of note, a decrease in V617F
allele burden greater than 30% of basal level was
observed in 13 patients, and in 3 essential thrombo-
cythemia patients the mutation was no longer detectable
after 5-55 months of treatment. In the same study, the
levels of V617 allele were also compared at a single time
point between a cohort of newly-diagnosed poly-
cythemia vera or essential thrombocythemia patients
and a second cohort was comprised of patients who had
been under hydroxyurea treatment for a median dura-
tion of 32 months. A lower amount of V617F allele was
found in hydroxyurea-treated polycythemia vera
patients (44% vs. 54% in PV patients analyzed at diag-
nosis) unlike in those with essential thrombocythemia in
whom any difference was minimal. Interestingly, in both
polycythemia vera and essential thrombocythemia,
changes in V617F allele burden under hydroxyurea were
more prominent in women than in males, suggesting
females are more sensitive to the drug than males. A sig-
nificant decrease in JAK2V617F burden has been also docu-
mented in 72% of 18 patients (9 PV and 9 ET) studied by
Ricksten et al; of note, only after four months of cytore-
ductive therapy with hydroxyurea were the levels of
mutant allele significantly reduced compared to those
pre-treatment.4
The aim of our study was to analyze changes in
JAK2V617F allele burden occurring during long-term follow
up in patients with polycythemia vera or essential
thrombocythemia and the relationships with hydrox-
yurea treatment. This two-center (Firenze and Bergamo,
Italy) retrospective study concerned 172 JAK2V617F mutat-
ed patients with a diagnosis of polycythemia vera or
essential thrombocythemia according to the WHO 2008
criteria. We included patients for whom at least two
sequential blood samples, drawn at an interval time of at
least six months, were available. The JAK2V617F allele load
was measured by a sensitive quantitative real-time PCR
in density-gradient purified granulocyte DNA according
to the method of Lippert et al;5 we used clone plasmids
of wild-type and V617F mutated JAK2 as standards.
Differences between median values of JAK2V617F allele
burden were tested by Wilcoxon’s matched-pairs signed-
ranks test. Repeated measure test for JAK2V617F mean
change over time, irrespective of diagnosis, was also cal-
culated to investigate a significant variance among
ordered time measures. JAK2 varianceMUT (% JAK2V617F in
last sample - % JAK2V617F in baseline sample) : (%
JAK2V617F in baseline sample x 100) was calculated as a
measure of relative changes in JAK2V617F allele burden
between the baseline and follow-up sample.1,2,6
There were 104 patients with polycythemia vera and
68 with essential thrombocythemia (median age 56
years, range 15-84; 49% female). Clinical characteristics
at diagnosis are reported in Table 1. The median follow-
up time was 3.1 years (range 0.6-26.1); no evolution to
myelofibrosis or acute leukemia occurred. The median
time elapsing from diagnosis to first (“baseline”) periph-
eral blood sample was nine months; six and 15 months
in polycythemia vera or essential thrombocythemia,
respectively. The median interval time between the
baseline and the follow-up sample (considered the last in
the case of multiple samples) in the whole patient popu-
lation was 27 months (range 6-60); 28 and 23 months for
polycythemia vera or essential thrombocythemia,
respectively. According to previous reports, the mean
V617F burden was significantly greater in polycythemia
vera than in essential thrombocythemia patients
(50±26% and 32±18%, respectively; P<0.0001).
Sixty-four patients, 40 with polycythemia vera and 24
with essential thrombocythemia, remained chemothera-
py-free during follow up (Group 1);  polycythemia vera
patients were managed with phlebotomies only plus
low-dose aspirin while essential thrombocythemia
patients received no drug at all or low-dose aspirin. One-
hundred and eight patients (63%), accounting for 61%
of polycythemia vera and 65% of essential thrombo-
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Table 1. Characteristics of the 172 patients included in the study.
All patients PV ET
N. patients 172 104 68
Male/Female 88/84 66/38 22/46
Disease duration, 3.1 (0.6-26.1) 3.2 (0.6-26.1) 2.5 (0.6-24.5)
years§ (range)
Age, years§ (range) 56 (15-84) 57 (17-79) 52 (15-84)
White cell count (x109/L)° 10.0±3.2 10.3±3.2 9.4±3.1
Hemoglobin (gr/dL)° 16.5±2.4 17.9±1.9 14.4±1.4
Hematocrit (%)° 49.7±8.2 54.1±7.3 43.1±4.0
Platelet count (x109/L)° 636±262 533±197 795±271
Patients with  51 (29%) 29 (28%) 22 (32%)
thrombotic events (%)
Patients with major 11 (6%) 5 (5%) 6 (9%)
hemorrhagic events (%) 
Cytoreductive therapy (%) 108 (63%) 64 (61%) 44 (65%)
Time between diagnosis   9 (0-298) 6 (0-298) 15 (0-279)
and first sample, mo§ (range)
Time between first 27 (6-60) 28 (6-60) 23 (6-60)
and last sample, mo§ (range)
JAK2V617F Allele burden (%) ° - 50±26 32±18
§Median value (range) is reported. °Mean value (±SD) is reported. 
cythemia patients, respectively, had received cytoreduc-
tive treatment with hydroxyurea. Of these, 44 patients
were chemotherapy-naive and started therapy within
two months after the basal blood sample was collected
(Group 2) whereas 64 patients were already on treat-
ment from a median of 57 (range 3-290) months at the
time of first genotyping (Group 3).
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Table 2. Individual JAK2V617F burden changes in Group 2 patients
with essential thrombocythemia or polycythemia vera.
% JAK2 V617F % JAK2 617F JAK2 Time between two 
baseline last sample varianceMUT assessments (mo)
ET patients
01 41 29 -29 36
02 44 40 -9 38
03 50 35 -30 40
04 41 37 -10 21
05 52 56 +8 36
06 32 38 +19 21
07 73 67 -8 7
08 32 17 -47 14
09 38 37 -3 12
10 34 28 -18 57
11 20 25 +25 45
12 26 4 -85 13
13 41 35 -15 13
14 27 13 -52 43
15 26 16 -38 44
16 25 16 -36 15
17 37 35 -5 27
18 24 27 +13 27
19 38 43 +13 25
20 68 45 -34 9
PV patients
01 59 57 -3 10
02 53 41 -23 10
03 40 41 +3 40
04 46 39 -15 34
05 47 26 -45 16
06 83 88 +6 33
07 39 21 -46 36
08 52 56 +8 34
09 71 50 -30 11
10 44 37 -16 25
11 35 23 -34 48
12 15 41 +173 19
13 3 30 +900 32
14 100 61 -39 26
15 40 56 +40 11
16 92 85 -8 12
17 15 45 +200 25
18 37 22 -41 19
19 93 43 -54 55
20 20 40 +100 37
21 14 42 +200 41
22 50 56 +12 17
23 98 89 -9 34
24 25 13 -48 41
JAK2 varianceMUT was calculated as  (% JAK2V617F in last sample - % JAK2V617F
in baseline sample) : (% JAK2V617F in baseline sample x100).
Figure 1. Boxplot representation of the JAK2V617F allele burden
measured in a baseline and subsequent blood sample (last sam-
ple) in three group of patients with ET or PV: patients chemother-
apy-free (Group 1, panel A), patients who were chemotherapy
naïve at baseline sample and were on hydroxyurea at last sample
(Group 2, panel B), and patients who were already on hydroxyurea
at baseline samples and remained continuously under the drug up
to the last sample analyzed (Group 3, panel C). Statistically signif-
icant differences, tested by the Wilcoxon matched-pairs signed-
ranks test, between baseline and last samples, are reported in the
figure.
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In the group of untreated patients (Group 1) (Figure
1A) the median interval time between baseline and fol-
low-up sample was 26 months (range 6-60) for poly-
cythemia vera patients and 24 months (range 6-59) for
essential thrombocythemia patients. The JAK2V617F allele
burden remained stable during the follow-up period:
44% and 49% in the baseline and follow-up sample,
respectively, in polycythemia vera patients, and 27%
and 31%, respectively, in essential thrombocythemia
patients. Therefore, we found no evidence for a time-
dependent increase of V617F allele burden in untreated
polycythemia vera and essential thrombocythemia
patients in a medium-term follow up (median 26
months). As a matter of fact, in a previous study in
essential thrombocythemia patients we were able to
document significantly raised levels of mutant allele
compared to newly-diagnosed patients only in those
who had a history of disease of at least ten years.7
Among patients belonging to Group 2, which included
24 polycythemia vera and 20 essential thrombocythemia
patients, the median interval time between baseline and
follow-up sample was 29 months (range 10-55) for poly-
cythemia vera patients and 26 months (range 7-57) for
essential thrombocythemia patients. The JAK2V617F allele
burden was 45% and 41% (P=0.7) in the baseline and
follow-up sample in polycythemia vera patients, respec-
tively, and 38% and 35% in that of essential thrombo-
cythemia patients (P=0.024) (Figure 1B). The changes in
individual JAK2V617F allele burden at the second time
point during continuous hydroxyurea treatment are
reported in Table 2. By using the criteria for evaluating
“molecular response” in polycythemia vera or essential
thrombocythemia that have been recently published by
a European LeukemiaNet consensus conference8 we
found that no patient with either disease had a “com-
plete response”, i.e. the reduction of JAK2V617F allele bur-
den to an undetectable level. A “partial response”, i.e. a
reduction of 50% or more from baseline in patients with
less than 50% mutant allele burden at baseline, or a
reduction of  25% or more in those with more than 50%
at baseline, was observed in 3 essential thrombo-
cythemia patients (15%) and 3 polycythemia vera
patients (12%). On the contrary, in 5 essential thrombo-
cythemia (25%) patients the burden of V617F allele
increased by a median value of 13% (range 8-25%)
while in 10 polycythemia vera (41%) patients the
mutant allele burden increased by 70% (range 3-900%).
In patients in Group 3 (Figure 1C), which included 40
polycythemia vera and 24 essential thrombocythemia
patients, the median time interval between baseline and
follow-up sample was 28 months for both polycythemia
vera (range 6-54) and essential thrombocythemia
patients (range 6-60). The JAK2V617F allele burden was
58% and 61% in the baseline and follow-up sample in
polycythemia vera patients, respectively, and 34% and
38% that of essential thrombocythemia patients
(P=0.039). Considering polycythemia vera and essential
thrombocythemia patients all together, there was a sta-
tistically significant increase in the median value of
V617F allele burden over time from 36% to 41% in the
basal and the follow-up sample, respectively (P=0.023,
repeated measure test).
As a whole, when we considered patients receiving
hydroxyurea, we observed a low (less than 10%), yet
statistically significant, reduction in V617F allele burden
only in the group of newly treated essential thrombo-
cythemia patients; this is in accordance with another
study.1 When considering individual cases, a modifica-
tion of mutated allele burden consistent with the defini-
tion of “partial response” according to the European
LeukemiaNet criteria involved 15% of essential throm-
bocythemia patients and 12% of  polycythemia vera
patients in our series. Furthermore, the fact that the
amount of V617F allele showed a tendency towards rais-
ing levels in essential thrombocythemia and poly-
cythemia vera patients who were already under hydrox-
yurea at the time of baseline evaluation and remained
continuously under drug for a median of 28 months
(patients in Group 3) suggests that the small changes in
allele burden measured in Group 2 patients may be of lit-
tle significance. Since only 6 patients showed a molecu-
lar response, we did not attempt to correlate it with clin-
ical parameters.
In summary, we conclude that in untreated patients
with polycythemia vera and essential thrombocythemia,
changes in V617F allele burden occur very smoothly
over years. This means that the routine serial quantita-
tive determinations of V617F allele do not provide clini-
cally useful information and are not cost-effective.
However, in cases where the modified phenotype sug-
gests evolution to post-PV/post-ET myelofibrosis, a
comparison of allele burden with that measured at diag-
nosis might be worthwhile since an increased load of
mutated JAK2 burden has been implicated in myelofi-
brotic transformation.9,10 Finally, we confirmed previous
reports that hydroxyurea can reduce the JAK2V617F allele
burden in subsets of patients.1,3,4 However, we suggest
that serial determination of V617F allele burden in
patients receiving hydroxyurea should be confined to
clinical studies since its role in routine patient manage-
ment remains unclear.
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